Related Experiment Video
Updated: May 10, 2026
Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
Published on: February 28, 2019
Expression of the tumour-suppressor maspin in temporal bone carcinoma
Gino Marioni1, Elisabetta Zanoletti, Paola Stritoni
1Otolaryngology Section, Department of Neurosciences, Padova University, Padova, Italy. gino.marioni@unipd.it
Aims:
Although it accounts for fewer than 0.2% of all head and neck tumours, temporal bone squamous cell carcinoma (SCC) is an aggressive malignancy with a poor prognosis in advanced cases. Novel therapeutic strategies should be developed focusing on specific targeted therapies. Maspin is a serpin showing tumour-suppressing activity which has therapeutic potential. The present study is the first to investigate maspin expression in temporal bone SCCs, using a series of 29 cases.
Methods And Results:
Cytoplasmic maspin expression was significantly higher in the group of patients whose SCC did not recur than in the group experiencing recurrences (P = 0.029), and in G1-G2 SCCs than in G3 cases (P = 0.001). cT correlated with recurrence rate (P = 0.05), disease-free survival (DFS) (P = 0.008) and disease-specific survival (DSS) (P = 0.0043), and pT and pathological regional lymph node status correlated with recurrence rate (P = 0.008 and P = 0.03, respectively), DFS (P = 0.017 and P = 0.0049, respectively) and DSS (P = 0.008 and P = 0.0009, respectively).
Conclusions:
Although further studies using larger series are required, our preliminary findings suggest that cytoplasmic maspin expression has promise as a prognostic indicator of disease recurrence in temporal bone SCC, and that reactivating maspin functions in association with apoptosis-inducing or anti-angiogenic chemotherapeutic agents might be an important goal in the treatment of temporal bone SCC.
Insights
Higher maspin expression in temporal bone squamous cell carcinoma (SCC) correlates with lower recurrence rates. Maspin may serve as a prognostic indicator for SCC, suggesting therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Temporal bone squamous cell carcinoma (SCC) is a rare but aggressive malignancy.
- Maspin, a serpin, exhibits tumor-suppressing properties and therapeutic potential.
- Investigating maspin expression in temporal bone SCC is crucial for understanding prognosis and developing targeted therapies.
Purpose of the Study:
- To investigate maspin expression in temporal bone SCC.
- To evaluate the correlation between maspin expression and clinical outcomes.
- To explore maspin's potential as a prognostic biomarker.
Main Methods:
- Analysis of maspin expression in 29 temporal bone SCC cases.
- Correlation of cytoplasmic maspin levels with tumor recurrence, disease-free survival (DFS), and disease-specific survival (DSS).
- Assessment of clinical tumor stage (cT), pathological tumor stage (pT), and lymph node status.
Main Results:
- Higher cytoplasmic maspin expression was associated with no recurrence and lower tumor grades (G1-G2 vs. G3).
- Clinical tumor stage (cT) correlated with recurrence rate, DFS, and DSS.
- Pathological tumor stage (pT) and lymph node status significantly correlated with recurrence rate, DFS, and DSS.
Conclusions:
- Cytoplasmic maspin expression shows promise as a prognostic indicator for temporal bone SCC recurrence.
- Reactivating maspin, potentially with apoptosis-inducing or anti-angiogenic agents, could be a therapeutic strategy.
- Further studies with larger cohorts are needed to validate these findings.
